Analysis | Published:

Lessons from 60 years of pharmaceutical innovation

Nature Reviews Drug Discovery volume 8, pages 959968 (2009) | Download Citation



Despite unprecedented investment in pharmaceutical research and development (R&D), the number of new drugs approved by the US Food and Drug Administration (FDA) remains low. To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analysing data on the companies that introduced the 1,200 new drugs that have been approved by the FDA since 1950. This analysis shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model. The implications of these findings and options to achieve sustainability for the pharmaceutical industry are discussed.

Key points

  • New molecular entities (NMEs) are produced at the same rate today as they were 50 years ago.

  • The industry has averaged one NME per company every 6 years, and its most successful firms have averaged almost one NME per year. No firm has ever approached the two or three NMEs per year that many companies say they need to secure their future.

  • Nothing that companies have done to increase NME output has worked, including mergers, acquisitions, reorganizations and process improvement.

  • The industry output is not depressed, but reflects the limitations of its R&D model.

  • Costs per NME have increased at a double-digit rate for decades, and are now well into several billions of dollars at many companies.

  • The share of NMEs captured by large companies has declined and is now below that of small companies, despite the greater spending on R&D by large companies.

  • The industry is caught in a vice between an NME output that is essentially constant, and likely to remain so, and the cost of producing it that is increasing exponentially.

  • Overcoming these difficulties will require bold initiatives, such as open innovation, that may take companies far from their comfort zone

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    PhRMA. Pharmaceutical Industry Profile 2009. PhRMA website [] (2009).

  2. 2.

    Burrill & Company. Biotech 2008: a 20/20 vision to 2020. Available from the BayBio website [] (2008).

  3. 3.

    Collaborative innovation for the post-crisis world. Boston Globe (2 Feb 2009).

  4. 4.

    Science Business: The Promise, The Reality, and The Future of Biotech (Harvard Business School Press, Boston, Massachusetts, 2006).

  5. 5.

    in Issues in Pharmaceutical Economics (ed. Chien, R. I.) 151–187 (Lexington Books, Lexington, 1979).

  6. 6.

    , , & Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107–142 (1991).

  7. 7.

    The Cost of Developing a New Drug (Pharmaceutical Manufacturers Association, Washington, 1987).

  8. 8.

    , & The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

  9. 9.

    US Congress, Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks, and Rewards, OTA-H-522 (US Government Printing Office, Washington, 1993).

  10. 10.

    Lehman Brothers. Drug R&D Costs, Success Rates, and Emerging Technologies (1997) in PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2000 (Parexel International Corp, Waltham, 2000). This document also includes another estimate of NME costs from the US Office of Technology Assessment for the year 1990.

  11. 11.

    , The cost of biopharmaceutical R&D. Manage. Decis. Econ. 28, 469–479 (2007).

  12. 12.

    Innovations in the Pharmaceutical Industry (Johns Hopkins University Press, Baltimore, 1976).

  13. 13.

    in The Economics of Drug Innovation (ed. Cooper, J. D.) 109–124 (The American University, Washington, 1970).

  14. 14.

    Research and development costs and returns: the U. S. pharmaceutical industry. J. Polit. Econ. 80, 70–85 (1972). This article contains estimates of NME costs before and after the 1962 Kefauver–Harris amendment.

  15. 15.

    National Academy of Engineering. The Competitive Status of the U.S. Pharmaceutical Industry (National Academies Press, Washington, 1983).

  16. 16.

    , & Estimating the effects of regulation on international innovation. J. Law Econ. 21, 133–163 (1978).

  17. 17.

    Pharmaceutical Innovation (John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts, 2007).

  18. 18.

    Time-cost trade-offs in uncertain empirical research projects. Nav. Res. Logistics Q. 13, 71–82 (1966).

  19. 19.

    & in The Economics of Corporate Governance and Mergers (eds Gugler, K. & Yurtoglu, B.) 262–287 (Edward Elgar, Cheltenham, 2008).

  20. 20.

    An acute talent for innovation. Financial Times (2 Feb 2009).

  21. 21.

    Good science and the marketplace for drugs: a conversation with Jean-Pierre Garnier. Health Aff. 22, 119–127 (2003).

  22. 22.

    Profile: Alpheus Bingham. Nature Biotech. 25, 1072 (2007).

  23. 23.

    Science by the masses. Science 319, 1750–1752 (2008).

  24. 24.

    , & A more rational approach to new product development. Harvard Bus. Rev. (March 2008).

  25. 25.

    et al. The new landscape of neglected disease drug development (The Wellcome Trust, London, 2006).

  26. 26.

    et al. The malaria product pipeline (The George Institute for International Health, Sydney, 2007).

  27. 27.

    Ending an epidemic: the international AIDS vaccine initiative pioneers a public–private partnership. Innovations 1, 52–66 (2006).

  28. 28.

    Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov. 5, 723–729 (2006).

  29. 29.

    India takes an open source approach to drug discovery. Cell 133, 201–203 (2008).

  30. 30.

    & Distributed drug discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases. J. Comb. Chem. 11, 3–13 (2009).

  31. 31.

    The X Prize's new frontier: genomics. Technology Review (5 Oct 2006).

  32. 32.

    (interview) Innovation networks: looking for ideas outside the company. Knowledge@Wharton (14 Nov 2007).

  33. 33.

    Choosing the right incentive strategy for research and development in neglected diseases. Bull. World Health Organ. 84, 376–381 (2006).

  34. 34.

    An audience with Steven Paul. Nature Rev. Drug Discov. 8, 14 (2009).

  35. 35.

    The Black Swan: The Impact of the Highly Improbable (Random House, London, 2007).

  36. 36.

    Hollywood Economics: How Extreme Uncertainty Shapes the Film Industry (Routledge, London, 2003). An important book about the dynamics of blockbuster economics, and its first rigorous mathematical treatment.

  37. 37.

    Rebuilding the R&D engine in big pharma. Harvard Bus. Rev. 86, 68–76 (2008). A candid assessment by the former CEO of GSK of the process culture that dominates pharmaceutical R&D.

  38. 38.

    United States Life Tables, 2004. National Center for Health Statistics website [] (2004).

  39. 39.

    Create Marketplace Disruption (FT Press, Upper Saddle River, 2008).

  40. 40.

    Can you spot the early warnings? Strategy & Innovation 3, no. 2 (March/April 2005).

  41. 41.

    Seeing What's Next: Using Theories of Innovation to Predict Industry Change (Harvard Business School Press, Boston, Massachusetts, 2004).

  42. 42.

    & Innovation and Industrial Leadership: Lessons from Pharmaceuticals (Center for Transatlantic Relations, Washington, 2008).

  43. 43.

    , & Interorganizational collaboration and the locus of innovation. Admin. Sci. Q. 41, 116–145 (1996).

Download references


I thank the late Armen Tashjian (Harvard School of Public Health and Harvard Medical School) for his unrelenting support, and M. Munos (Johns Hopkins School of Public Health) for her extensive feedback on previous versions of the manuscript.

Author information


  1. Lilly Corporate Center, Indianapolis, Indiana 46285, USA.;

    • Bernard Munos


  1. Search for Bernard Munos in:

Competing interests

B.M. is an employee of Eli Lilly and Company.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (box)

    What is a Poisson distribution?

  2. 2.

    Supplementary information S2 (box)

    Probability that the NME output of a company will exceed 2 or 3 per year

  3. 3.

    Supplementary information S3 (box)

    The Monte Carlo simulation tool


New molecular entity

(NME). A medication containing an active ingredient that has not been previously approved for marketing in any form in the United States. NME is conventionally used to refer only to small-molecule drugs, but in this article the term includes biologics as a shorthand for both types of new drug.

Prescription Drug User Fee Act

A US law passed in 1992 that allows the US Food and Drug Administration to collect fees from drug manufacturers to fund the new-drug approval process.

Orphan drug

A drug that is specifically developed for a disease that affects a patient population of fewer than 200,000 people in the United States. The Orphan Drug Act provides financial incentives to develop such drugs, including marketing exclusivity for that indication for 7 years after approval.

Open-source R&D

A broad-based participatory research model in which a virtual network of volunteers use online tools to address a problem in which they share an interest.

Disruptive innovation

A process to turn cutting-edge science into novel products with such superior features that they create vast new markets, which unsettles established products and technology.

Black swan

A metaphor that designates rare random events of key importance that reshape markets, industries and societies.

About this article

Publication history



Further reading